



HL

Yuqin Song | ASH 2018 | Tislelizumab (BGB-A317) in relapsed/refractory classical Hodgkin lymphoma

 Philippa Redondo | Dec 21, 2018

60th ASH Annual Meeting & Exposition, December 1-4 2018, San Diego, CA

Yuqin Song, Peking University Cancer Hospital, Beijing, CN

Interview Topic: Tislelizumab (BGB-A317) in relapsed/refractory classical Hodgkin lymphoma

© 2018 Scientific Education Support Ltd. This PDF is provided for personal use only. For wider or commercial use, please seek permission from secretariat@scientificeducationsupport.com and attribute the source as: <<http://www.lymphomahub.com/medical-information/yuqin-song-ash-2018-tislelizumab-bgb-a317-in-relapsed-refractory-classical-hodgkin-lymphoma>>